Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis
Herein, we report a case of alopecia universalis and transient accommodation spasm presented after alemtuzumab administration in a patient previously treated with fingolimod. To the best of our knowledge, this is the first report of accommodation spasm as an acute adverse effect of alemtuzumab. Trea...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-10-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864221127476 |
| _version_ | 1811226738143789056 |
|---|---|
| author | Dimitrios Tzanetakos Marianthi Breza John S. Tzartos Georgios Bontzos Aigli G. Vakrakou Alexandros Dermentzoglou Ilias Gkizis Georgios Smoustopoulos Maria-Eleptheria Evangelopoulos Leonidas Stefanis Costantinos Kilidireas |
| author_facet | Dimitrios Tzanetakos Marianthi Breza John S. Tzartos Georgios Bontzos Aigli G. Vakrakou Alexandros Dermentzoglou Ilias Gkizis Georgios Smoustopoulos Maria-Eleptheria Evangelopoulos Leonidas Stefanis Costantinos Kilidireas |
| author_sort | Dimitrios Tzanetakos |
| collection | DOAJ |
| description | Herein, we report a case of alopecia universalis and transient accommodation spasm presented after alemtuzumab administration in a patient previously treated with fingolimod. To the best of our knowledge, this is the first report of accommodation spasm as an acute adverse effect of alemtuzumab. Treatment with alemtuzumab in relapsing-remitting multiple sclerosis has been identified as a risk factor for developing secondary autoimmunity within the follow-up period (peak 18–36 months from the first infusion) such as thyroid disorders. This case highlights the need for postmarketing surveillance and the significance of reporting rare side effects related to alemtuzumab; its high efficacy should be weighted with potentially severe adverse events when making a therapeutic decision. Further studies in larger cohorts are needed to elucidate pathomechanisms of alemtuzumab. |
| first_indexed | 2024-04-12T09:30:22Z |
| format | Article |
| id | doaj.art-833663fa08a344058271ac6cc3ff2821 |
| institution | Directory Open Access Journal |
| issn | 1756-2864 |
| language | English |
| last_indexed | 2024-04-12T09:30:22Z |
| publishDate | 2022-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-833663fa08a344058271ac6cc3ff28212022-12-22T03:38:22ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642022-10-011510.1177/17562864221127476Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosisDimitrios TzanetakosMarianthi BrezaJohn S. TzartosGeorgios BontzosAigli G. VakrakouAlexandros DermentzoglouIlias GkizisGeorgios SmoustopoulosMaria-Eleptheria EvangelopoulosLeonidas StefanisCostantinos KilidireasHerein, we report a case of alopecia universalis and transient accommodation spasm presented after alemtuzumab administration in a patient previously treated with fingolimod. To the best of our knowledge, this is the first report of accommodation spasm as an acute adverse effect of alemtuzumab. Treatment with alemtuzumab in relapsing-remitting multiple sclerosis has been identified as a risk factor for developing secondary autoimmunity within the follow-up period (peak 18–36 months from the first infusion) such as thyroid disorders. This case highlights the need for postmarketing surveillance and the significance of reporting rare side effects related to alemtuzumab; its high efficacy should be weighted with potentially severe adverse events when making a therapeutic decision. Further studies in larger cohorts are needed to elucidate pathomechanisms of alemtuzumab.https://doi.org/10.1177/17562864221127476 |
| spellingShingle | Dimitrios Tzanetakos Marianthi Breza John S. Tzartos Georgios Bontzos Aigli G. Vakrakou Alexandros Dermentzoglou Ilias Gkizis Georgios Smoustopoulos Maria-Eleptheria Evangelopoulos Leonidas Stefanis Costantinos Kilidireas Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis Therapeutic Advances in Neurological Disorders |
| title | Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis |
| title_full | Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis |
| title_fullStr | Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis |
| title_full_unstemmed | Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis |
| title_short | Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis |
| title_sort | alemtuzumab induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis |
| url | https://doi.org/10.1177/17562864221127476 |
| work_keys_str_mv | AT dimitriostzanetakos alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT marianthibreza alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT johnstzartos alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT georgiosbontzos alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT aigligvakrakou alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT alexandrosdermentzoglou alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT iliasgkizis alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT georgiossmoustopoulos alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT mariaeleptheriaevangelopoulos alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT leonidasstefanis alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis AT costantinoskilidireas alemtuzumabinducedalopeciauniversalisandtransientaccommodationspasminapatientwithmultiplesclerosis |